Feinstein Institutes is currently conducting three clinical trials of patients infected with moderate to severe Covid-19 infection who were admitted to Northwell Health hospitals.
The aim is to determine effective treatments that could improve recovery and expedite hospital discharge.
Northwell Health president and CEO Michael Dowling said: “We’ve joined with three outstanding companies to immediately begin clinical trials for patients now suffering from Covid-19 and are determined to do all we can to stop the virus in its tracks.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Alliance with Gilead
Feinstein Institutes will assess the safety and efficacy of Gilead’s remdesivir in decreasing the intensity and duration of the novel coronavirus infection in hospitalised patients in two clinical trials.
The first randomised global trial will recruit up to 400 patients with severe Covid-19 and will evaluate two dosing durations of the drug given intravenously.
Conducted in alliance with Gilead, the second trial will compare two different durations of remdesivir to current standard of care in up to 600 patients with moderate disease globally.
Gilead already launched Phase III clinical trials of the drug to treat Covid-19 in adults.
Partnership with Regeneron and Sanofi
Feinstein Institutes has partnered with Regeneron and Sanofi to perform an adaptive, randomised trial of sarilumab in around 400 severe or critical hospitalised patients at various US sites.
The trial is designed to investigate the safety and efficacy of the anti-interleukin-6 antibody.
IL-6’s role in Covid-19-related pneumonia is supported by preliminary findings from a Chinese trial. China recently approved the use of an IL-6 inhibitor for severe or critical Covid-19 treatment.
Earlier this month, Sanofi and Regeneron launched a clinical programme of rheumatoid arthritis drug sarilumab (Kevzara) to treat hospitalised, severe Covid-19 patients.